Core Viewpoint - GeneIII Biotech has initiated a global evidence-based journey for Ergothioneine (EGT) in collaboration with Singapore's National University and Temasek Life Sciences Laboratory, marking a significant breakthrough in China's biotech sector for global research and brand development [1][2][3]. Group 1: Collaboration with Singapore National University - The partnership with Professor Barry Halliwell's team at Singapore National University focuses on clinical research design, emphasizing the link between low EGT levels and age-related degenerative diseases [1]. - Halliwell's extensive research supports the antioxidant and cellular protective mechanisms of EGT, highlighting its potential in improving neurological function and eye health [1][2]. - This collaboration is seen as a historic integration of scientific theory and industrial practice, providing authoritative guidance for product development in various applications of EGT [1][2]. Group 2: Partnership with Temasek Life Sciences Laboratory - GeneIII Biotech's visit to Temasek Life Sciences Laboratory aims to establish the world's first international clinical research on EGT for ovarian anti-aging, creating a comprehensive innovation system from basic research to industrial transformation [3]. - The collaboration is praised for reconstructing the global supply chain of EGT, with a focus on its mitochondrial protective capabilities as a key target for delaying reproductive aging [3][4]. - This partnership complements the collaboration with Singapore National University, enhancing GeneIII's research capabilities in the antioxidant application field [3]. Group 3: Collaboration with People's Daily - The launch of the "GeneIII Biotech × People's Daily 'Hardcore Jiangsu' co-branded gift box" signifies a dual trust system combining official endorsement and elite market validation [4][5]. - This collaboration illustrates GeneIII's journey from technological breakthroughs to global industrial applications, embodying the spirit of innovation promoted by Jiangsu [4][5]. - The recognition from over a hundred billion-level entrepreneurs in Jiangsu, alongside People's Daily's authoritative endorsement, establishes a robust trust framework for the brand [6]. Group 4: Clinical Validation by National Health Commission - GeneIII Biotech is the first company in the industry to conduct verifiable clinical trials for EGT in top-tier hospitals, setting a new benchmark for scientific rigor and independence [7]. - Clinical studies have demonstrated significant improvements in eye health and liver function, with specific metrics showing a reduction in discomfort and fatigue [7][8]. - Ongoing research is exploring EGT's effectiveness in various health areas, including postpartum health and cognitive function, further solidifying its market trust through transparent clinical data [8][9]. Group 5: Comprehensive Development Pathway - The integrated approach of linking theoretical research, mechanism exploration, brand authority, and clinical validation showcases GeneIII Biotech's effective transformation of EGT research into a competitive global model [9][10]. - This pathway redefines the role of Chinese biotech companies in global competition, emphasizing the importance of solid research foundations, authoritative endorsements, and rigorous clinical evidence in building market trust [10].

Group 1 - The company has reported that it is currently selling its ergotamine products through various platforms, including WeChat Mini Programs, Tmall, and JD.com [2] - The company has developed a strategic plan for the health and wellness sector and is making steady progress in its implementation [2]

Group 1 - The company has started selling its ergotamine series products through various platforms including WeChat Mini Program, Tmall, and JD.com [1] - The company has developed a corresponding plan for the development of the health sector and is currently making steady progress [1]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting strong performance in the sector [2]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 3.7% from November 7 to November 14, 2025, surpassing the market average [3][4]. - The Double 11 shopping festival saw significant sales for domestic brands, with Proya leading sales on Tmall for three consecutive years, indicating a sustained rise of domestic brands [9][30]. - Proya has re-entered the men's skincare market, launching a new product line aimed at addressing various skincare needs, which is seen as a strategic move to enhance revenue and compete with international brands [30]. - Marubi Biotech announced plans for an H-share listing in Hong Kong to strengthen its capital base and international strategy, following similar moves by other domestic beauty brands [31]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index increased by 3.7%, with the cosmetics index up by 2.5% and personal care index up by 3.7%, indicating strong sector performance [3][4]. - The Double 11 sales event resulted in high single-digit growth in online GMV for beauty products, second only to home appliances and clothing [9]. Key Company Developments - Proya's Q3 2025 revenue reached 7.098 billion yuan, a year-on-year increase of 1.89%, with a net profit of 1.026 billion yuan, reflecting a stable performance despite a slight decline in Q3 [10][11]. - Marubi Biotech's revenue for the first three quarters of 2025 was 2.45 billion yuan, a 25.51% increase year-on-year, indicating strong growth potential [31]. Market Trends - The cosmetics retail sector saw a 9.6% year-on-year growth in October 2025, driven by the Double 11 shopping festival, which boosted consumer demand [25][27]. - Domestic brands are gaining market share, with Proya and other local brands performing well against international competitors [34]. E-commerce Insights - Data from October 2025 shows that Proya achieved a GMV of 21.5 billion yuan across Tmall and Douyin, despite a 9% decline year-on-year, indicating resilience in a competitive market [24]. - The report highlights the importance of e-commerce channels for domestic brands, which are leveraging their advantages in pricing and local market insights to capture market share [34].

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty sector, with specific recommendations for companies like Maogeping and Shangmei Co. [4][9] Core Insights - The cosmetics and medical beauty sector underperformed the market during the reporting period, with the Shenwan Beauty Care Index declining by 3.1% [5] - The upcoming Double 11 shopping festival is expected to boost sales for Shangmei Co. and Maogeping, with strong performance anticipated on platforms like Douyin and Tmall [4][9] - Key companies such as Proya and Shanghai Jahwa reported mixed results, with Proya's revenue for Q3 2025 at 1.736 billion yuan, down 11.63% year-on-year, while Shanghai Jahwa's revenue grew by 28% to 1.483 billion yuan [10][15] Summary by Sections Industry Performance - The cosmetics and medical beauty sector showed a decline, with the Shenwan Cosmetics Index down 2.6% and the Shenwan Personal Care Index down 0.9% [5] - The top-performing stocks included *ST Meigu (+12.3%) and Jinsong New Materials (+6.2%), while Huaxi Biological and Beitaini saw declines of 7.8% and 7.4%, respectively [5] Company Performance - Proya's Q3 2025 revenue was 1.736 billion yuan, a decrease of 11.63% year-on-year, with a net profit of 227 million yuan, down 23.64% [10] - Shanghai Jahwa reported Q3 revenue of 1.483 billion yuan, an increase of 28%, with a net profit of 140 million yuan [15] - Ruoyuchen's Q3 revenue reached 819 million yuan, up 123.4% year-on-year, with a net profit of 33 million yuan [18] Market Trends - The 8th China International Import Expo showcased major international beauty brands, highlighting trends such as high-end market targeting and AI technology in beauty research and development [27] - The report indicates that the Chinese market is evolving into a global innovation hub for beauty products, with a focus on sustainability and green transformation [27] E-commerce Insights - The report provides data on the performance of domestic brands on platforms like Douyin and Tmall, with Shangmei Co. achieving significant growth in GMV [21] - The overall retail sales of cosmetics in September 2025 grew by 8.6%, driven by pre-Double 11 promotions [22][24]